MX2022000267A - Composiciones comprimidas de macitentan, metodos y usos de las mismas. - Google Patents

Composiciones comprimidas de macitentan, metodos y usos de las mismas.

Info

Publication number
MX2022000267A
MX2022000267A MX2022000267A MX2022000267A MX2022000267A MX 2022000267 A MX2022000267 A MX 2022000267A MX 2022000267 A MX2022000267 A MX 2022000267A MX 2022000267 A MX2022000267 A MX 2022000267A MX 2022000267 A MX2022000267 A MX 2022000267A
Authority
MX
Mexico
Prior art keywords
macitentan
compositions
compressed
relates
methods
Prior art date
Application number
MX2022000267A
Other languages
English (en)
Inventor
Serra João Pedro Silva
Pereira Ricardo José Camilo Ferreira
Original Assignee
Tecnimede Soc Tecnico Medicinal Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tecnimede Soc Tecnico Medicinal Sa filed Critical Tecnimede Soc Tecnico Medicinal Sa
Publication of MX2022000267A publication Critical patent/MX2022000267A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente divulgación también se refiere a composiciones comprimidas que comprenden una cantidad terapéuticamente eficaz de macitentán, un diluyente de alcohol de azúcar y un tensioactivo; también se refiere al procedimiento de obtención de dichas composiciones comprimidas, a composiciones farmacéuticas orales que las comprenden, y a su uso en el tratamiento de hipertensión arterial pulmonar; la presente divulgación también se refiere a composiciones farmacéuticas orales sólidas que comprenden una cantidad terapéuticamente eficaz de macitentán que simultáneamente presentan propiedades de estabilidad mejoradas y perfiles de disolución adecuados, lo que presenta una necesidad insatisfecha en el campo de la formulación farmacéutica de macitentán.
MX2022000267A 2019-07-05 2020-07-03 Composiciones comprimidas de macitentan, metodos y usos de las mismas. MX2022000267A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PT11563219 2019-07-05
EP19185065 2019-07-08
PCT/IB2020/056304 WO2021005478A1 (en) 2019-07-05 2020-07-03 Compressed macitentan compositions, methods and uses thereof

Publications (1)

Publication Number Publication Date
MX2022000267A true MX2022000267A (es) 2022-02-03

Family

ID=71899791

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000267A MX2022000267A (es) 2019-07-05 2020-07-03 Composiciones comprimidas de macitentan, metodos y usos de las mismas.

Country Status (11)

Country Link
US (1) US20220249381A1 (es)
EP (1) EP3993777B1 (es)
CN (1) CN114096239B (es)
AU (1) AU2020309223A1 (es)
BR (1) BR112022000117A2 (es)
CA (1) CA3144613A1 (es)
CL (1) CL2022000008A1 (es)
CO (1) CO2021017646A2 (es)
MX (1) MX2022000267A (es)
PE (1) PE20220593A1 (es)
WO (1) WO2021005478A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022258796A1 (en) * 2021-06-11 2022-12-15 Actelion Pharmaceuticals Ltd Dispersible tablet for oral administration
EP4154873A1 (en) * 2021-09-22 2023-03-29 Sanovel Ilac Sanayi Ve Ticaret A.S. The tablet comprising macitentan
WO2023128898A1 (en) * 2021-12-30 2023-07-06 Humanis Saglik Anonim Sirketi Pharmaceutical compositions comprising macitentan as active ingredient and other relevant excipients

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4245130B2 (ja) 2000-12-18 2009-03-25 アクテリオン ファーマシューティカルズ リミテッド 新規なスルファミド類
AU2006290309B2 (en) * 2005-09-12 2012-04-05 Actelion Pharmaceuticals Ltd. Stable pharmaceutical composition comprising a pyrimidine-sulfamide
PL2358374T3 (pl) 2008-11-17 2014-03-31 Takeda As Ulepszona stabilność rozpuszczania tabletek węglanu wapnia
DE14721256T1 (de) * 2013-04-22 2017-03-16 Sandoz Ag Pharmazeutische zusammensetzungen mit kristallinem macitentan
WO2014198178A1 (zh) * 2013-06-14 2014-12-18 杭州普晒医药科技有限公司 马西替坦晶体及其制备方法、其药物组合物和用途
IN201641002749A (es) 2016-01-25 2017-09-15 Hetero Research Foundation
CN107913256A (zh) 2016-10-08 2018-04-17 郑州泰丰制药有限公司 一种治疗肺动脉高压的马西替坦口腔崩解片及其制备方法
WO2018153925A1 (en) 2017-02-22 2018-08-30 Amneal Pharmaceuticals Company Gmbh Stable pharmaceutical compositions comprising macitentan
CN109260163A (zh) 2018-10-07 2019-01-25 威海云睿信息科技有限公司 一种马西替坦片剂组合物

Also Published As

Publication number Publication date
EP3993777A1 (en) 2022-05-11
CN114096239A (zh) 2022-02-25
WO2021005478A1 (en) 2021-01-14
CN114096239B (zh) 2024-04-12
EP3993777B1 (en) 2024-06-12
CL2022000008A1 (es) 2022-10-07
CA3144613A1 (en) 2021-01-14
BR112022000117A2 (pt) 2022-02-15
CO2021017646A2 (es) 2022-01-17
US20220249381A1 (en) 2022-08-11
AU2020309223A1 (en) 2022-03-03
PE20220593A1 (es) 2022-04-22

Similar Documents

Publication Publication Date Title
MX2022000267A (es) Composiciones comprimidas de macitentan, metodos y usos de las mismas.
MX2021004431A (es) Procesos novedosos.
WO2017068089A9 (en) Ferroportin inhibitors
PH12018502634A1 (en) Topical compositions of apremilast
MX2023006541A (es) Formulaciones de dosis fija.
WO2018115097A9 (en) Ophthalmic composition for treatment of dry eye disease
WO2015160843A8 (en) Ion channel activators and methods of use
MX2020012310A (es) Formulaciones de liberacion prolongada de colchicina y metodos de uso de las mismas.
MX2017007178A (es) Formulaciones liquidas estables de virus de vacuna.
WO2020172420A3 (en) Stable anhydrous cleanser concentrate formulation and method of making same
WO2016109217A3 (en) Btk inhibitors
IN2013MU03583A (es)
WO2016168553A8 (en) Deuterated obeticholic acid
WO2017134685A3 (en) Novel hydrazino compounds as btk inhibitors
WO2017040407A8 (en) Compositions and methods for the reduction or prevention of non-alcoholic steatohepatitis (nash)
MX2019004580A (es) Formulaciones farmaceuticas y metodos para prepararlas.
ZA201908610B (en) Il-15 protein complex pharmaceutical composition and uses thereof
WO2018084627A3 (en) Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone
PH12018502089A1 (en) Pharmaceutical composition of dapagliflozin
MX2022007707A (es) Comprimidos de edoxaban.
WO2017083266A8 (en) Novel formulations
WO2020013777A3 (en) Tablet formulations comprising metformin and sitagliptin
PH12018501876A1 (en) Crystalline(2s,4r)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof
MX2022005305A (es) Formulacion oral de x842.
WO2018105941A3 (ko) 탈모방지 또는 발모촉진용 주사용 조성물